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Poor graft function (PGF) is a serious complication after allogeneic hematopoietic stem cell transplantation
(allo-HSCT). Whether abnormalities of the bone marrow (BM) microenvironment are involved in the path-
ogenesis of PGF is unclear. In the present prospective nested case-control study, 19 patients with secondary
PGF, 38 matched patients with good graft function (GGF) after allo-HSCT, and 15 healthy donors (HDs) were
enrolled. The cellular elements of the BM microenvironment, including endosteal cells, perivascular cells, and
vascular cells, were analyzed by ﬂow cytometry as well as hematoxylin and eosin and immunohistochemical
staining in situ. The median time to occurrence of secondary PGF was 90 days post-transplantation (range,
58 to 264 days). The patients with PGF showed markedly hypocellular marrow (10% versus 45% versus 45%;
P < .0001) with scattered hematopoietic cells and signiﬁcantly lower CD34þ cells (0.07% versus 0.26% versus
0.26%; P < .0001), endosteal cells (4 per high-power ﬁeld [hpf] versus 16 per hpf versus 20 per hpf; P < .001),
perivascular cells (0.008% versus 0.10% versus 0.12%; P < .0001), and endothelial progenitor cells (0.008%
versus 0.16% versus 0.18%; P < .0001) compared with GGF allo-HSCT recipients and HDs, respectively.
Multivariate analyses revealed that endothelial progenitor cells (odds ratio, 150.72; P ¼ .001) and the
underlying disease (odds ratio, 18.52; P ¼ .007) were independent risk factors for secondary PGF. Our results
suggest that the impaired BM microenvironment may contribute to the occurrence of secondary PGF
post-HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an effective treatment for hematologic malignan-
cies. Nevertheless, poor graft function (PGF), including
primary PGF and secondary PGF, occurs in 5% to 27% of
patients and remains a serious complication after allo-HSCT
[1-6]. An increased risk of PGF has been reported in
HLA-mismatched [7] and/or major ABO-mismatched trans-
plant settings [8]. Numerous factors, including immunologic
rejection of the hematopoietic stem cells (HSCs) graft, mye-
lotoxic agents, graft-versus-host disease (GVHD), septicemia,
viral infection (eg, cytomegalovirus [CMV], human herpes
virus type 6, parvovirus), and possibly transplant-related
factors, such as conditioning regimen intensity and stem
cell source, have been shown to correlate with PGF [1,3,4,9].
The mechanisms underlying PGF remain to be elucidated,
although the available data suggest that effective engraft-
ment is the result of interaction between the supporting
bone marrow (BM) microenvironment and HSCs [10]. In this
regard, several studies have previously reported a role of BM
stromal impairment in long-term chemotherapy -induced
hematopoietic failure using long-term BM culture (LTBMC)dgments on page 1473.
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13.07.014systems and clonogenic assays in vitro as surrogate methods
for evaluating the in vivo ability of stromal cells to support
hematopoiesis in patients [11-14]. The hematopoietic sup-
porting function of BM stromal cells has been shown to be
impaired before autologous peripheral blood stem cell
transplantation (auto-PBSCT) [15,16] and even 1 year after
auto-PBSCT [17]. Moreover, stromal defects also have been
reported in recipients of allo-HSCT and patients with aplastic
anemia using similar methods [18-20]. However, LTBMC
typically results in conﬂuent layers of adherent cells
composed of a heterogeneous population of stromal cells
including ﬁbroblasts, endothelial cells, adipocytes, and
other types [19]. Native stromal cells are infrequent, partic-
ularly early after allo-HSCT, hindering LTBMC and clonogenic
assays [18].
More recently, hematopoiesis has been reported to depend
on special BMmicroenvironments knownas “niches” inwhich
HSCs reside [21]. The BM osteoblastic, perivascular, and
vascular niche compartments have been anatomically and
functionally validated in mouse studies [22-24]. Endosteal
cells, perivascular cells, and vascular endothelial cells have
been revealed as key players in the maintenance of HSCs
by providing signals that regulate cell self-renewal, differen-
tiation, and quiescence in mice [22-24]. The equivalents of
the candidate murine BM niche components have not been
studied systematically in humans, however, particularly
in patients undergoing allo-HSCT. We speculate that the
occurrence of PGF ismost likely associatedwith abnormalitiesTransplantation.
Table 1
Characteristics of allo-HSCT Recipients with Secondary PGF and GGF
Characteristic Secondary PGF Cases (n ¼ 19)* GGF Cases (n ¼ 38)* P Valuey
BM evaluated time post-HSCT, d, median (range) 90 (58-264) 90 (30-270) .61
BMB cellularity, %, median (range) 10 (5-15) 45 (30-50) <.0001
BM microenvironment elements, median (range)
EPCs, % 0.008 (0.001-0.14) 0.16 (0.07-0.25) <.0001
CD146þ perivascular cells, % 0.008 (0.001-0.03) 0.10 (0.02-0.23) <.0001
Osteopontin-positive endosteal cells, n per hpf 4 (2-8) 16 (10-20) <.0001
CD34þ microvessels, n per trabecular bone 2 (0-4) 4 (2-6) <.0001
Blood cell count, median (range)
WBC, 109/L 1.73 (0.32-5.34) 5 (3.10-7.60) <.0001
ANC, 109/L 1.10 (0.16-6.50) 3.65 (1.55-6.38) <.0001
Hb, g/L 76 (56-103) 120 (78-151) <.0001
PLT, 109/L 17 (9-142) 119 (61-243) <.0001
Age at HSCT, yr, median (range) 27 (16-57) 35.5 (16-55) .48
Sex, male/female, n 9/10 23/15 .40
Underlying disease, n
Acute myelogenous leukemia 4 9 1.00
Acute lymphocytic leukemia 9 17 1.00
Chronic myelogenous leukemia 2 4 1.00
Myelodysplastic syndrome 4 8 1.00
Status at HSCT, n .11
Standard risk 16 25
High risk 3 13
Time from diagnosis to HSCT, mo, median (range) 12 (4-20) 10 (2-30) .32
Stem cell source 1.00
BM and PBSCs 17 34
PBSCs 2 4
Transplanted total nucleated cell dose, 108/ kg, median (range) 8.06 (5.34-15.34) 7.59 (3.50-10.08) .12
Transplanted CD34þ cell dose, 106/kg, median (range) 2.38 (1.23-3.96) 2.26 (0.90-3.94) .80
Donor match, n
HLA-identical sibling donor 2 10 .30
HLA-partially matched related donor 15 22 .15
HLA-matched unrelated donor 2 4 1.00
Sex mismatch, n
Female to male 5 6 .48
Female to female 1 2 1.00
Male to female 9 11 .15
Male to male 4 15 .24
ABO mismatch, n
None 13 27 1.00
Minor 2 2 .59
Major 4 10 .75
Pre-HSCT cycles of chemotherapy, n, median (range) 4 (0-8) 4 (0-10) .86
Conditioning, n .29
Busulfan/cyclophosphamide 2 10
Busulfan/cyclophosphamide þ ATG 17 28
History of GVHD, n 8 20 .58
History of CMV reactivation, n 11 20 .78
Duration of anti-CMV therapy, d, median (range) 21 (16-42) 22 (16-56) .80
* Group matching criteria included age at HSCT (1 year), pre-HSCT cycles of chemotherapy (1 cycle), disease status at HSCT, and BM microenvironment
evaluated time after HSCT (5 days). For each case, 2 GGF controls were selected at random from the same cohort at which the secondary PGF occurred (risk-set
sampling).
y Continuous variables were compared using the Mann-Whitney U test, and differences in frequency between the 2 groups were compared using the
chi-squared test. The criterion for statistical signiﬁcance was P < .05.
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To conﬁrm our hypothesis, we analyzed the BM niche
components, including endosteal cells, perivascular cells,
and vascular endothelial cells, whichwere recently identiﬁed
in mice, using ﬂow cytometry and immunohistochemistry
(IHC) in human BM samples. In addition, we prospectively
analyzed whether the levels of the aforementioned com-
partments of the BM microenvironment in allo-HSCT recip-
ients with secondary PGF differed from those in allo-HSCT
recipients without PGF and healthy donors.
PATIENTS AND METHODS
Patients and Controls
In this prospective nested case-control study, cases were identiﬁed from
a cohort of 410 patients who underwent allo-HSCT for hematologic malig-
nancies between April 1, 2012, and April 15, 2013, at the Institute ofHematology, Peking University. A total of 19 patients who had developed
secondary PGF after allo-HSCT were eligible. For each case, 2 matched
controls with good graft function (GGF) (n ¼ 38) were selected at random
from the same cohort at the onset of secondary PGF and were matched
according to the following criteria: age at HSCT (1 years), pre-HSCT cycles
of chemotherapy (1 cycle), disease status at HSCT, and the time at which
the BM microenvironment was evaluated after HSCT (5 days) ("risk-set
sampling") [25]. The characteristics of the secondary PGF cases and controls
are summarized in Table 1.
BM samples from 15 healthy donors (HDs) were used as healthy
controls. The healthy control group comprised 7 males and 8 females,
ranging in age from 18 to 50 years (median, 28 years). The study was
approved by the Ethics Committee of Peking University People’s Hospital,
and written informed consent was obtained from all subjects before study
entry, in accordance with the Declaration of Helsinki.Diagnosis of GGF and PGF
GGF was deﬁned as a persistent successful engraftment, as marked by an
absolute neutrophil cell (ANC) count >0.5  109/L for 3 consecutive days,
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level >70 g/L without transfusion support, beyond day þ28 post-HSCT. PGF
(both primary and secondary) was deﬁned as the presence of 2 or 3 cytopenic
counts (ANC 0.5  109/L, PLT 20  109/L, or Hb 70 g/L) for at least 3
consecutive days beyond day þ28 post-transplantation with transfusion
requirement, associated with hypoplastic-aplastic BM, in the presence of
complete donor chimerism. Patients with evidence of severe GVHD or
hematologic relapse after transplantation were excluded. Primary PGF was
deﬁned as a slow or incomplete recovery of blood counts (ANC 0.5  109/L,
PLT20 109/L) at least 28 days after allo-HSCT. Secondary PGF was deﬁned
as a recurrent pancytopenia to levels fulﬁlling diagnostic criteria for PGF after
achieving GGF, in the absence of severe GVHD or hematologic relapse.
Transplantation Protocols
Donor selection, HLA typing, and stem cell harvesting were conducted as
described previously [26-31]. The conditioning therapy for HLA-mismatched
and unrelated matched allo-HSCT recipients included a modiﬁed busulfan/
cyclophosphamide plus thymoglobulin (ATG) regimen, which consisted of
i.v. busulfan (3.2 mg/kg/day) on days8 to6, i.v. cyclophosphamide (1.8 g/
m2/day) on days5 to4, oral simustine (MeCCNU, 250mg/m2) once on day
3, and i.v. ATG (2.5 mg/kg/day; Sang Stat, Lyon, France) on days 5 to 2.
Patients inHLA-mismatched allo-HSCT received i.v. cytarabine at 4 g/m2/day,
whereas patients in unrelated matched allo-HSCT received a lower dose of
cytarabine (2 g/m2/day) on days 10 and 9. In matched sibling trans-
plantations, patients received a regimen identical to that of HLA-mismatched
patients without ATG except with oral hydroxycarbamide (80 mg/kg) on
day10 and a lower dose of cytarabine (2 g/m2/day) on day 9. All subjects
received granulocyte colony-stimulating factor (G-CSF)-mobilized BM and
blood cells. The transplanted grafts were both recombinant human G-CSF
(rhG-CSF)-mobilized peripheral blood stem cells (PBSCs) and BM cells from
matched sibling or HLA-mismatched sibling donors or PBSCs from unrelated
donors. Cyclosporine A, mycophenolate mofetil, and short-term metho-
trexate were used for post-HSCT GVHD prophylaxis.
All allo-HSCT recipients were screened before transplantation for cyto-
megalovirus (CMV) serostatus. Weekly quantitative real-time PCR for
detection of CMV DNA was used to detect CMV reactivation in the blood
after allo-HSCT. CMV infection was treated with ganciclovir or foscarnet as
described previously [32].
After allo-HSCT, rhG-CSF was administered to HLA-mismatched and
unrelated matched allo-HSCT recipients at 5 mg/kg/day s.c. from dayþ6 until
the neutrophil count reached 0.5  109/L for 3 consecutive days. rhG-CSF
was not used after allo-HSCT with matched sibling transplants. Patients
received RBC or PLT transfusions when the Hb value fell to70 g/L or the PLT
count dropped to 20  109/L.
Clinical Deﬁnitions and Evaluation
Hematopoietic engraftment post-transplantation was deﬁned as
reconstitution of both neutrophil and PLT numbers. Neutrophil reconstitu-
tion was deﬁned as the ﬁrst 3 consecutive days with an ANC >0.5  109/L,
and PLT reconstitution was deﬁned as the ﬁrst 7 consecutive days of levels
>20  109/L. Chimerism analyses were performed by DNA ﬁngerprinting for
short tandem repeats in blood samples and/or chromosome ﬂuorescence in
situ hybridization of BM samples. Full donor chimerism was deﬁned as
detection of no recipient hematopoietic or lymphoid cells with either of the
foregoing methods. Standard-risk patients were deﬁned as those in ﬁrst or
second complete remission of acute leukemia, in ﬁrst chronic phase of
chronicmyelogenous leukemia, orwithmyelodysplastic syndrome. All other
patients were classiﬁed as high risk. Hematologic relapse was deﬁned as the
reappearance of blasts in the blood or BM (>5%) or any extramedullary site
after complete remission using common morphological criteria. GVHD was
classiﬁed as acute or chronic based on published criteria [33,34].
Immunophenotypic Analysis of Cellular Components in the BM
Microenvironment
BM aspiration was performed for a comparative study of the immuno-
phenotypic features of the BM environment elements by ﬂow cytometry in
patients with secondary PGF, those with GGF and HDs. Here, 5 mL of fresh
BM was harvested for the quantiﬁcation of the BM environment cellular
composition with mouse anti-human CD45, CD34, CD146, and vascular
endothelial growth factor receptor 2 (VEGFR2) monoclonal antibodies (BD
Biosciences, San Jose, CA). Multicolor ﬂow cytometry analyses were per-
formed using a FACSCalibur (BD Biosciences), with 2,000,000 events
collected routinely. Aliquots of the unstained samples served as negative
controls. Data were analyzed with FlowJo software (Tree Star, Ashland, OR).
Histological Analysis of the BM Microenvironment
BM trephine biopsies (BMBs) were obtained from 19 patients with
secondary PGF, 38 matched patients with GGF, and 15 HDs. BMBs wereobtained from the posterior superior iliac spine, ﬁxed with 4% para-
formaldehyde for 1 hour, dehydrated with 70% ethanol, embedded in
parafﬁn, and cut into 5-mm-thick sections. H&E staining was performed on
each tissue section. IHC with rabbit anti-human osteopontin, CD34, and
CD146 (all from Abcam, Cambridge, MA) was performed after dehydration
with graded alcohol and antigen retrieval with heated citrate buffer
according to standard protocols. Following the manufacturer’s instructions,
sections of BMBs with known monoclonal/polyclonal antibody were
included as positive controls in each batch of staining. Tissue sections
incubated only with secondary antibody seved as controls. Each section was
examined by light microscopye (Axiovert 200; Carl Zeiss, Jena, Germany).Methods of Assessment in Histological Analysis
BMB cellularity was assessed by visual examination and classiﬁed into 3
groups [35]: normocellular (30% to 50% of intertrabecular space occupied by
hematopoietic tissue), hypercellular (>50% of intertrabecular space occu-
pied by hematopoietic tissue), and hypocellular (<30% of intertrabecular
space occupied by hematopoietic tissue). The number of endosteal cells was
determined as the number of osteopontin-positive cells per hpf on the line
of the trabecular bone. The number of CD146þ perivascular cells per
microvessel was counted. BM microvessel enumeration was performed
according to the method described by Perez-Atayde et al. [36] in the BMB
sections by IHC using a CD34-reactive monoclonal antibody. Any brown-
staining endothelial cell or endothelial cell cluster that was clearly sepa-
rated from adjacent microvessels was considered a single, countable
microvessel. For each case, the median value of vessels per trabecular bone
was recorded. A comparison of routinely stained H&E sections was made
with the information obtained from IHC. Two readers evaluated slides in
a blind fashion.Statistical Analysis
Characteristics of the patients with secondary PGF and those with GGF
were compared using the chi-squared test for categorical variables and the
Mann-Whitney U test for continuous variables. Statistical analyses among
the 3 groups were performed using 1-way ANOVA, and the Fisher least
signiﬁcant difference test was used for multiple comparisons between
2 groups when P < .05. Cutoff points of endothelial progenitor cells (EPCs),
CD146þ perivascular cells, osteopontin-positive endosteal cells, and the
occurrence of secondary PGF were estimated by a receiver operating char-
acteristic (ROC) analysis. Factors with a P value <.10 on univariate logistic
analysis were included in the multivariate logistic regression analysis, and
factors with a P value <.05 were considered independently associated with
PGF. All procedures were performed using SPSS 16.0 (IBM, Armonk, NY) and
Prism 5.0 (GraphPad Software, La Jolla, CA). A P value <.05 was considered
statistically signiﬁcant.RESULTS
Patient Characteristics
Nineteen patients with secondary PGF, along with 38
matched patients with GGF after allo-HSCT, were enrolled in
this study. The median time to secondary PGF was 90 days
post-transplantation (range, 58 to 264 days). To minimize
the potential inﬂuence of the time interval after allo-HSCT,
the patients with secondary PGF and GGF underwent BM
microenvironment testing at a matched median time point
after allo-HSCT (90 days versus 90 days; P > .05). In addition,
PCR DNA ﬁngerprinting of the short tandem repeats of the
recipient BM cells was used to conﬁrm 100% donor chime-
rism in these patients.
As shown in Table 1, none of the demographic and clinical
characteristics evaluateddincluding age, sex, underlying
disease, disease status pretransplantation, median time from
diagnosis to transplantation, stem cell source, transplanted
total nucleated cell dose, CD34þ cell dose, donor HLA match,
sex/ABO mismatch, pretransplantation cycles of chemo-
therapy, conditioning, history of GVHD or CMV, and duration
of anti-CMV therapydshowed a statistically signiﬁcant
difference between the allo-HSCT recipients with secondary
PGF and those with GGF (P > .05).
Figure 1. BMB cellularity was signiﬁcantly lower in the patients with secondary PGF (A3) compared with the patients with GGF (A2) and the HDs (A1). Original
magniﬁcation, 10.
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Hemograms showed signiﬁcant pancytopenia in patients
with secondary PGF compared with the GGF controls.
Median WBC (1.73  109/L versus 5  109/L; P < .0001), ANC
(1.1 109/L versus 3.65  109/L; P < .0001), Hb (76 g/L versus
120 g/L; P < .0001), and PLT (17  109/L versus 119  109/L; P
< .0001) values were dramatically lower in the secondary
PGF group compared with the GGF group (Table 1).
The secondary PGF group demonstrated shrinkage of the
BM hematopoietic space, leading to hypocellular BM with
depletion in all hematopoietic lineages, as well as the pres-
ence of interstitial dilated areas with medullary lakes, as
evidenced by dilated vessel lumen sinuses and adipocyte-
rich marrow. In contrast, the control group had normocel-
lular BM with a predominantly granulocytic cell populationFigure 2. Percentages of CD34þ cells (B), perivascular cells (C), and EPCs (D) in the BM
with GGF and HDs, even though there was no difference in transplanted CD34þ cell d
done using 1-way ANOVA. MNCs, mononuclear cells.(Figure 1). BMB cellularity was signiﬁcantly lower in the
secondary PGF group compared with the GGF and HD groups
(10% versus 45% versus 45%; P < .0001).
Quantiﬁcation of CD34þ Cells, Perivascular Cells, and
EPCs in BM by Flow Cytometry
As shown in Figure 2, the median percentages of CD34þ
cells in BM mononuclear cells (BMMNCs) was signiﬁcantly
lower in the patients with secondary PGF compared with
those with GGF and HDs (0.07% versus 0.26% versus 0.26%; P
< .0001), even though similar amounts of CD34þ cells were
transplanted in the PGF and GGF groups (2.38  106/kg
versus 2.26  106/kg; P > .05).
According to Corselli et al. [37], CD146þ perivascular cells
can be considered a bona ﬁde human equivalent of thewere signiﬁcantly lower in patients with secondary PGF compared with those
ose between the secondary PGF and GGF groups (A). Statistical analyses were
Figure 3. Immunophenotypic analysis of perivascular cells within the human BM microenvironment. Shown are representative FACS analyses of CD45-CD34-CD146þ
perivascular cells from an HD donor (A), a patients with GGF (B), and a patient with secondary PGF (C).
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described in mice [38]. Using the same gating strategies, we
detected CD45-CD34-CD146þ perivascular cells in BM
derived from HDs and allo-HSCT recipients (Figure 3). The
median percentage of perivascular cells in BMMNCs was
signiﬁcantly higher in HDs and patients with GGF compared
with patients with secondary PGF (0.12% versus 0.10% versus
0.008%; P < .000/1) (Figure 2C).Figure 4. Immunophenotypic analysis of EPCs within the human BM microenvironm
shown in an HD.EPCs are known to play an important role within the BM
microenvironment [39]. As shown in Figure 4,
CD45eCD34þVEGFR2þ cells in unselected BMMNCs were
identiﬁed as EPCs by ﬂow cytometry following to a previously
reported protocol [40]. The level of EPCs in BMMNCs was
dramatically lower in patients with secondary PGF compared
with those with GGF and HDs (0.008% versus 0.16% versus
0.18%; P < .0001) (Figure 2D).ent. Representative FACS gating strategies of CD45-CD34þVEGFR2þ EPCs are
Figure 5. In situ expression of hematopoietic niche marker by endosteal cells in human BMBs. The trabecular bone was lined by fewer detectable endosteal cells in
patients with secondary PGF compared with patients with GGF and HDs, as evaluated by H&E (A1-A3) and IHC staining with osteopontin (B1-B3). Original
magniﬁcation, 40. Red arrows indicate endosteal cells.
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Cells, and Vascular Endothelial Cells in the BM
Flow cytometry analysis demonstrated a signiﬁcantly
decreased frequency of perivascular cells and EPCs in the
patients with secondary PGF compared with those with GGF
and HDs. Histological analysis of the recipient BMBs was
performed to further examine the expression of in situ
markers on the subsets identiﬁed in previous murine studies
to characterize the human BM microenvironment post-
transplantation.
The trabecular bone was lined by fewer detectable
endosteal cells in the patients with secondary PGF (4 per hpf)
compared with those with GGF (16 per hpf) and HDs (20 per
hpf) (P < .05) after IHC staining with anti-osteopontin
(Figure 5). In addition, compared with the patients with
GGF and HDs, those with secondary PGF had a signiﬁcantly
lower median number of microvessels in the BM when
stainedwith CD34 (2 versus 4 versus 6 per trabecular bone; P
< .05) (Figure 6). Consistent with ﬁndings reported by Cor-
selli et al. [37], IHC performed on BMBs revealed the presence
of CD146-expressing perivascular cells surrounding micro-
vessels and capillaries in HDs and allo-HSCT recipients
post-transplantation (Figure 7). Consistent with our ﬂow
cytometry data, the median percentage of perivascular cells
was lower in the patients with secondary PGF on IHC stainingwith CD146 (6 versus 4 versus 1 per microvessel; P < .05). In
contrast, the numbers of endosteal cells, perivascular cells,
and CD34þ vascular cells did not differ signiﬁcantly between
the patients with GGF and the HDs.
Risk Factors for Secondary PGF
On univariate logistic regression, underlying disease type,
history of GVHD, and BM microenvironment elements,
including EPCs, CD146þ perivascular cells, and osteopontin-
positive endosteal cells, were associated with secondary
PGF (P < .10). On multivariate logistic regression analysis,
EPCs (odds ratio [OR], 150.72; 95% conﬁdence interval [CI],
7.85 to 2893; P ¼ .001) and underlying disease type (OR,
18.52; 95% CI, 2.23 to 142.86; P ¼ .007) emerged as inde-
pendent factors inﬂuencing the occurrence of secondary PGF
(Table 2).
DISCUSSION
This prospective nested case-control study demonstrates
for the ﬁrst time that the anatomically and phenotypically
deﬁned cellular elements of the human BM microenviron-
ment, including endosteal cells, perivascular cells, and
vascular cells, share a similar phenotype with the BM niche
components recently described in mice [22-24]. Of note, the
frequency of the aforementioned cellular elements was
Figure 6. In situ expression of hematopoietic niche marker by sinusoidal endothelial cells in human BMBs. Signiﬁcantly fewer microvessels were detected in the
patients with secondary PGF compared with those with GGF and HDs, as evaluated by H&E (A1-A3) and IHC staining with CD34 (B1-B3). Original magniﬁcation, 40.
Red arrows indicate microvessels.
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compared with those with GGF and HDs. Our results suggest
that the abnormalities of the BM microenvironment may
contribute to the occurrence of secondary PGF after allo-
HSCT.
Emerging evidence from mouse studies suggests that
endosteal cells, perivascular cells, and EPCs are preferentialFigure 7. In situ expression of hematopoietic niche marker by perivascular cells in
surrounding microvessels compared with patients with GGF and HDs, as demonstrate
perivascular cells.supporting cells for HSCs in the BM microenvironment [22-
24]. Osteopontin, a bone matrix protein that is particularly
abundant in the endosteum, is produced by both osteoblasts
and osteoclasts and exerts many effects on HSCs. The resi-
dence of transplantedWT Lin-Sca1þKITþ hematopoietic stem
progenitor cells at the endosteum was found to be lower in
nonablated osteopontin-deﬁcient mice compared with WThuman BMBs. The patients with secondary PGF had fewer perivascular cells
d by IHC with CD146 (A1-A3). Original magniﬁcation, 40. Red arrows indicate
Table 2
Univariate and Multivariate Analyses of Risk Factors for Secondary PGF
Factors Univariate Analysis Multivariate Analysis
P Value OR 95 % CI P Value
Demographics
Sex, female versus male .27
Age, per decade .81
Disease characteristics
Diagnosis, myelodysplastic syndrome versus leukemia .04* 18.52 2.23-142.86 .007y
Status, high-risk versus low-risk
Pre-HSCT chemotherapy cycles, per cycle .70
Transplant characteristics
Donor match, ISD versus PMRD versus MUD .15
HLA disparity, 2 loci versus 0-1 locus .10
Sex mismatch, FM versus FF versus MF versus MM .12
ABO mismatch, none versus minor versus major mismatch .21
Stem cell source, BM þ PBSCs versus PBSC 1.00
Conditioning, modiﬁed Bu/Cy þ ATG versus other .15
Transplanted total mononuclear cells, 7.37  108/kg versus <7.37  108/kg .45
Transplanted CD34þ cells, 2.3  106/kg versus <2.3  106/kg .42
Transplant-related complications
History of GVHD, yes versus no .03*
History of CMV, yes versus no .11
BM microenvironment elements
Evaluated time, post-HSCT days .33
EPCs, <0.055% versus 0.055%z <.0001* 150.72 7.85-2893 .001y
CD146þ perivascular cells, <0.025% versus 0.025%x <.0001*
Osteopontin-positive endosteal cells, <12 per hpf versus 12 per hpf{ <.0001*
ISD indicates HLA-identical sibling donor; PMRD, HLA-partial matched related donor; MUD, HLA-matched unrelated donor; FM, female to male; FF, female to
female; MF, male to female; MM, male to male.
* P < .10 in univariate analysis.
y P < .05 in multivariate analysis.
z EPCs were divided into 2 risk groups according to the ROC cutoff point, with a sensitivity of 100% and speciﬁcity of 89.5%.
x CD146þ perivascular cells were divided into 2 risk groups according to the ROC cutoff point, with a sensitivity of 89.5% and speciﬁcity of 84.2%.
{ Osteopontin-positive endosteal cells were divided into 2 risk groups according to the ROC cutoff point, with a sensitivity of 76.3% and speciﬁcity of 83.2%.
Y. Kong et al. / Biol Blood Marrow Transplant 19 (2013) 1465e14731472mice [41]. CXCL12-abundant reticular cells and perivascular
cells have been shown to contribute to the hematopoietic
“perivascular niche,” as well as to the pericyte ancestry of
mesenchymal stem cells and adipocytes in mice [38]. Corselli
et al. [37] have conﬁrmed that CD146þ perivascular cells can
be considered the human equivalent of the hematopoietic
perivascular niche components recently described in mice.
EPCs, phenotypically identiﬁed via coexpression of VEGFR2
and CD34, are a type of BM-derived cells that may contribute
structurally to neoangiogenesis [36]. In a mouse trans-
plantation model, VEGFR2-/- mice demonstrated delayed BM
vascular regeneration and hematopoietic recovery after total
body irradiation, and the systemic administration of anti-
VEGFR2 antibody inhibited HSC engraftment [42]. Nord-
lander et al. [43] further suggested that donor-speciﬁc
antibodies to EPCs may be involved in graft failure in
patients after allo-HSCT.
In the present study, patients with secondary PGF
demonstrated markedly lower frequencies of osteopontin-
positive endosteal cells, CD146þ perivascular cells, and EPCs
comparedwith patientswithGGFandHDs.Most importantly,
multivariate analysis identiﬁed frequency of EPCs as an
independent risk factor for secondary PGF. Considering the
important role of the aforementioned cellular elements in
supporting hematopoiesis [22-24,37], our data suggest that
impairment of the BM microenvironment may lead to
secondary PGF in allo-HSCT recipients. In contrast to previous
studies [13-18], we investigated changes in endosteal cells,
CD146þ perivascular cells, and vascular endothelial cells,
speciﬁc cellular elements that represent the osteoblastic
niche, perivascular niche, and vascular niche, respectively
[22-24,37].Because prompt and stable engraftment is dependent on
both HSCs and the BM microenvironment [10], we also
investigated CD34þ hematopoietic and progenitor cells [44].
We found a signiﬁcantly lower percentage of CD34þ cells in
the BM of patients with secondary PGF compared with
patients with GGF, even though the transplanted CD34þ cell
dose was similar in the 2 groups of patients. In addition, BMB
sections from patients with secondary PGF showedmarkedly
hypocellular marrow with scattered hematopoietic cells and
signiﬁcantly lower levels of endosteal cells, perivascular cells,
and vascular cells comparedwith BMB sections from patients
with GGF. Thus, it plausible that the impaired BM microen-
vironment may hamper the self-renewal, proliferation, and
differentiation of infused normal CD34þ cells in allo-HSCT
recipients.
In conclusion, this prospective nested case-control study
provides evidence that endosteal cells, perivascular cells, and
vascular endothelial cells are quantitatively reduced in
patients with secondary PGF, suggesting that an impaired
BM microenvironment may hamper hematopoietic recovery
in the osteoblastic, perivascular, and vascular niches after
allo-HSCT. Our study offers a guide for functionally charac-
terizing the molecular interactions between human HSCs
and their BM microenvironments, thereby providing insight
into how the BM microenvironment controls HSCs fate in
patients with secondary PGF, which may eventually lead to
improved hematopoietic reconstitution after allo-HSCT.
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